Two investment firms Fidelity Management & Research and T. Rowe Price Group led a $150m Series E financing round in Inscripta, a life science technology company, with participation from D1 Capital Partners and Durable Capital Partners, as well as existing investors Foresite Capital, Counterpoint Global - Morgan Stanley and JS Capital. “In addition to our excitement about the Onyx platform, we see further future potential with our innovation, which is captured by our IP portfolio of nearly 100 issued US patents. To this end, we are fortunate to have the support of some of the world’s most notable investors who share our enthusiasm for the long-term opportunity to build transformative technology and an impactful organization,” Sri Kosaraju, Inscripta President and CEO.